Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors

References

• Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14(1):2. doi:10.1186/s13045-020-01026-6
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol. 2017;3(7):944–952. doi:10.1001/jamaoncol.2016.6728
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338. doi:10.1016/S0140-6736(06)69446-4
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. doi:10.1016/S0140-6736(12)61857-1
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–934. doi:10.1016/S1470-2045(20)30168-6
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun. 2005;338(3):1307–1315. doi:10.1016/j.bbrc.2005.09.150
   PubMed Web of Science ®Google Scholar
• Liang L, Yan XE, Yin Y, Yun CH. Structural and biochemical studies of the PDGFRA kinase domain. Biochem Biophys Res Commun. 2016;477(4):667–672. doi:10.1016/j.bbrc.2016.06.117
   PubMed Web of Science ®Google Scholar
• Nannini M, Tarantino G, Indio V, et al. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRalpha mutation in a metastatic GIST patient responding to imatinib. Sci Rep. 2019;9(1):2172. doi:10.1038/s41598-018-38028-x
   PubMedGoogle Scholar
• Mazzocca A, Napolitano A, Silletta M, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019;11:1758835919841946. doi:10.1177/1758835919841946
   Web of Science ®Google Scholar
• Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer. 2019;120(6):577–578. doi:10.1038/s41416-019-0388-7
   PubMed Web of Science ®Google Scholar
• Norman RA, Ferguson AD, Ferguson AD. Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci. 2012;33:1873–3735. doi:10.1016/j.tips.2012.03.005
   Web of Science ®Google Scholar
• Gajiwala KS. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009;2009:1091–6490.
   Google Scholar
• Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2010;21(2):208–215. doi:10.1093/annonc/mdp291
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959–1968. doi:10.1016/j.ejca.2009.02.011
   PubMed Web of Science ®Google Scholar
• Yeh C-N, Chen M-H, Chen -Y-Y, et al. A Phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget. 2017;8(27):44121–44130. doi:10.18632/oncotarget.17310
   PubMedGoogle Scholar
• Bauer S, George S, von Mehren M, Heinrich MC. Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Front Oncol. 2021;11:672500. doi:10.3389/fonc.2021.672500
   PubMed Web of Science ®Google Scholar
• Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738–51 e9. doi:10.1016/j.ccell.2019.04.006
   PubMed Web of Science ®Google Scholar
• Gebreyohannes YK, Wozniak A, Zhai ME, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res. 2019;25(2):609–618. doi:10.1158/1078-0432.CCR-18-1858
   PubMed Web of Science ®Google Scholar
• Evans EA-O, Gardino AK, Kim JA-O, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;2017:1946–6242.
   Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935–946. doi:10.1016/S1470-2045(20)30269-2
   PubMed Web of Science ®Google Scholar
• George S, Jones RL, Bauer S, et al. Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy. Oncologist. 2021;26(4):E639–E49. doi:10.1002/onco.13674
   PubMed Web of Science ®Google Scholar
• Kang Y-K, George S, Jones RL, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic gi stromal tumor: a randomized, open-label phase III study. J Clin Oncol. 2021;39(28):3128–3139. doi:10.1200/JCO.21.00217
   PubMed Web of Science ®Google Scholar
• Serrano C, Marino-Enriquez A, Tao DL, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019;120(6):612–620. doi:10.1038/s41416-019-0389-6
   PubMed Web of Science ®Google Scholar
• Apsel Winger B, Cortopassi WA, Garrido Ruiz D, et al. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. Cancer Res. 2019;79(16):4283–4292. doi:10.1158/0008-5472.CAN-18-3139
   PubMed Web of Science ®Google Scholar
• Heinrich M, von Mehren M, Jones RL, Bauer S, Kang Y. Avapritinib is highly active and well-tolerated in patients with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA. presented at Connective Tissue Oncology Society 2018 Annual Meeting; 2018; Rome, Italy.
   Google Scholar
• George S, Heinrich M, Chi P, et al. Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Ann Oncol. 2018;29:viii576–viii7. doi:10.1093/annonc/mdy299.002
   Web of Science ®Google Scholar
• Chi P, Janku F, Heinrich M, et al. Abstract C077: updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)2019. C077-C p. Mol Cancer Ther. 2019;18(12 Suppl):C077–C077. doi:10.1158/1535-7163.TARG-19-C077
   Web of Science ®Google Scholar
• Rose S. News in brief: testing ripretinib against sunitinib in GIST. Cancer Discov. 2022;2022:OF1–OF.
   Google Scholar
• Heinrich MC, Jones RL, Gelderblom H, et al. INTRIGUE_A phase III_ randomized, open-label study to evaluate the efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor. Presented in ASCO Plenary Series: January Program; 2022.
   Google Scholar
• Mehren M, Heinrich M, George S, et al. Clinical benefit with ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: long-term update from the phase 3 INVICTUS study. Presented at CTOS 2021; November 10–13, 2021; 2021.
   Google Scholar
• Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol. 2020;38(28):3294–3303. doi:10.1200/JCO.20.00522
   PubMed Web of Science ®Google Scholar
• George S, Chi P, Heinrich MC, et al. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021;155:236–244. doi:10.1016/j.ejca.2021.07.010
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur, J Cancer. 1999;35(13):1773–1782. doi:10.1016/S0959-8049(99)00229-4
   PubMed Web of Science ®Google Scholar
• Heinrich MC, George S, Zalcberg J, et al. Quality of Life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with Gastrointestinal Stromal Tumors (GIST): analyses from INVICTUS. J Clin Oncol. 2020;38(Suppl):11535. doi:10.1200/JCO.2020.38.15_suppl.11535
   Google Scholar